Personalized and targeted medicine for rare lung and other cancers
SOMERVILLE, MA —December 6, 2022— ANDARIX Pharmaceuticals, a leader
in the discovery and development of targeted peptide therapy for cancer
announced today that it will present its clinical strategy and results at the
upcoming clinical trials in rare diseases conference.
The Clinical Trials in Rare Diseases Conference 2022 is focused on exploring the
challenges and opportunities for planning and conducting clinical studies in rare disease.
The virtual conference will take place on December 7, 2022.
Tozaride is a novel, best-in-class cancer therapy based on a radio-labeled
somatostatin peptide analogue. Early clinical studies of Tozaride demonstrated
that it is well tolerated and may produce prolonged stable disease and improved
overall survival in advanced lung cancer patients whose disease has continued
to progress after failing other therapies. Tozaride targeted radiotherapy
represents a new treatment paradigm which is expected to yield significant
clinical benefit for both lung cancer (SCLC, NSCLC), and pancreatic cancer
patients. Along with its companion diagnostic that helps identify patients most
likely to respond – those with sufficient expression of the peptide’s target –
Tozaride could provide another treatment option for patients who are not eligible
for, or who have not responded to current therapies.
About Andarix Pharmaceuticals
Andarix Pharmaceuticals is at the forefront of personalized therapies for cancer,
developing both the imaging agents that can identify appropriate patients, as well
as the targeted therapies for these patients. The company’s products have
progressed through early clinical development. The Andarix technology is based
on a proprietary somatostatin peptide conjugate applicable to lung, pancreatic,
neuroendocrine, and other cancers. Extensive research has demonstrated that
somatostatin receptors are highly up-regulated on several solid tumors,
particularly lung, neuroendocrine, and pancreatic tumors. To learn more about
Andarix, please visit www.andarix.com .